• Next Post
  • Previous Post

test

/ Uncategorized

Share the Post

About the Author

Related Posts

Aadi Bioscience to Present at Ladenburg Thalmann 2021 Virtual Healthcare Conference
Aadi Bioscience Announces FDA Approval of its First Product FYARRO™ for Patients with Locally Advanced Unresectable or Metastatic Malignant Perivascular Epithelioid Cell Tumor (PEComa)
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 (PRECISION 1)
A Phase 2, Open-Label, Single-Arm, Prospective, Multi-Center Study of nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer
Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines
Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors
Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009) Independent Reviewed Data Released from the AMPECT Registration Trial in Advanced PEComa
Analysis of inactivating alterations in TSC1 and TSC2 in advanced genitourinary (GU) cancers from a real-world patient population in the Foundation Medicine genomic database

Comments

Comments are closed.

  • Next Post
  • Previous Post